Vantictumab Explained

Vantictumab is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]

This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]

It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.

Phase I trials have been completed for pancreatic cancer, non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer[5] [6] and in 2020 for pancreatic cancer.[7]

Notes and References

  1. Web site: Statement on a nonproprietary name adopted by the USAN Council . PDF . 28 Nov 2012 . N12/155 . .
  2. OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance. 12 January 2015.
  3. Web site: Annual Report on Form 10-K . OncoMed Pharmaceuticals, Inc. . https://web.archive.org/web/20170113004651/http://investor.shareholder.com/oncomed/secfiling.cfm?filingID=1564590-16-14426&CIK=1302573 . 13 January 2017 .
  4. News: BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept. Reuters. 10 April 2017.
  5. Web site: Finally, targeted therapies for triple-negative breast cancer . June 2016 . Medical Xpress .
  6. Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, Stagg B, Uttamsingh S, Brachmann RK, Farooki A, Mita M . Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer . Breast Cancer Research and Treatment . 184 . 1 . 53–62 . November 2020 . 32803633 . 7572714 . 10.1007/s10549-020-05817-w .
  7. Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ . A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer . Investigational New Drugs . 38 . 3 . 821–830 . June 2020 . 31338636 . 7211194 . 10.1007/s10637-019-00824-1 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vantictumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.